Home Health News FDA Restricts Use of Immunotherapies in Gastric, Esophageal Cancers By News Health 3 months Ago Share on FacebookShare on Twitter (MedPage Today) — The FDA narrowed the indications for pembrolizumab (Keytruda) and nivolumab (Opdivo) in gastric, gastroesophageal junction (GEJ), and esophageal cancers, according to letters sent to the respective drugmakers. The agency had… Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/116000 Author : Publish date : 2025-06-10 19:00:00 Copyright for syndicated content belongs to the linked Source. Categories: Health News Related Content Diversity in Med School Acceptances Dips Following Ruling By News Health August 27, 2025 CDC Director Ousted After Just Weeks, Reports Say By News Health August 27, 2025 Medical Schools, Residency Programs Need to Add More Nutrition Education, HHS Says By News Health August 27, 2025 One in Seven Adults Started a GLP-1 Agent After Bariatric Surgery By News Health August 27, 2025 How Can I Cultivate Healthcare Leadership Skills? By News Health August 27, 2025 Brain Performance Varies With Menopausal Hormone Therapy By News Health August 27, 2025